Multicentre trial of naproxen and phenylbutazone in acute gout.
Open Access
- 1 February 1977
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 36 (1) , 80-82
- https://doi.org/10.1136/ard.36.1.80
Abstract
Naproxen 750 mg as a single dose followed by 250 mg three times daily has been compared with phenylbutazone 200 mg four times daily for 48 hours followed by 200 mg three times daily for treatment of acute gout in an open study on 41 patients. The drugs were equally effective with few and relatively mild side effects. Naproxen is a useful alternative agent for the treatment of acute gout.This publication has 20 references indexed in Scilit:
- It happened on the way to the XIII international congress on rheumatology in kyoto and after I had arrivedArthritis & Rheumatism, 1975
- Urate crystal arthritis in animals lacking hageman factorArthritis & Rheumatism, 1974
- Naproxen. A new non-hormonal anti-inflammatory agent. Studies in rheumatoid arthritis.Annals of the Rheumatic Diseases, 1974
- Comparison of indomethacin and phenylbutazone in acute gout.Annals of the Rheumatic Diseases, 1973
- A Double-Blind Cross-Over Study of Naproxen and Indomethacin in Patients with Rheumatoid ArthritisScandinavian Journal of Rheumatology, 1973
- Experience Francaise Du Traitement De La Crise De Goutte Aigue Par Le Naproxen - C 1674Scandinavian Journal of Rheumatology, 1973
- New Haven survey of joint diseases: The prediction of serum uric acid in a general populationJournal of Chronic Diseases, 1969
- Treatment of primary gout: The present status (The W. Paul Holbrook Memorial Lecture)Arthritis & Rheumatism, 1965
- GoutArthritis & Rheumatism, 1962
- Oral phenylbutazone in the treatment of acute gouty arthritisThe American Journal of Medicine, 1956